Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Neoplasms Malignant Liver Metastases Disease factors Histologically or cytologically-confirmed diagnosis of colorectal cancer (CRC) Metastatic or recurrent CRC, deemed surgically or medically unresectable Subjects have received two or more standard available therapies known to prolong survival and for which they would be considered eligible, whether in adjuvant or metastatic setting. Such therapies should regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine, if appropriate (e.g., and or their variants). Subjects that are unable to receive oxaliplatin and/or irinotecan due to allergy or hypersensitivity, or due to concerns regarding the side effects of oxaliplatin and/or irinotecan, will be allowed to receive less than two lines of standard therapies prior to enrollment to this study Patients must have at least two liver metastases, separated by ≥2 cm, and measured in at least one dimension (longest diameter) as ≥2 cm by CT/MRI. One of the metastases must be amenable to biopsy and SBRT. General considerations Age ≥18 years ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A) Life expectancy of ≥ 3 months Patients must have normal organ and marrow function as defined below  Disease factors / Tumor characteristics Has an MSI-H phenotype or a known MMR deficiency Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. Previous treatments and trials Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 3 weeks of the first dose of treatment Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.° Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. Comorbidities, medications and immune modulation agents Has a known additional malignancy that is progressing or requires active treatment. Exceptions basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with type I diabetes mellitus, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Subjects that require intermittent use of bronchodilators or local steroids, e.g., inhaled or topical steroids, at a dose of less than the equivalent of 10mg prednisone daily, would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study Has evidence of interstitial lung disease or active, non-infectious pneumonitis